IntroductionChronic pain management remains a challenge for physicians (Argoff et al., ; Birklein et al., ; Finnerup et al., ), particularly as available treatments are only modestly effective in reducing pain. According to a recent meta‐analysis on pharmacotherapy for neuropathic pain, the number needed to treat (NNT) for commonly prescribed drugs ranged from 3 to 6 for a defined goal of just 30 to 50% reduction in pain intensity (Finnerup et al., ). Antidepressants (tricyclics, serotonin and norepinephrine reuptake inhibitors), anti‐epileptics (gabapentin, pregabalin) and opioid agents are commonly prescribed drugs. Unfortunately, they are frequently associated with side effects that result in reduced dosages and limited efficacy (Finnerup et al., ). As a consequence, discovering new medications and exploring optimal pharmacological associations are still significant fields of research in chronic pain management.Ketamine, an NMDA antagonist and anaesthetic agent, was first synthesized in 1962 and is still in use today (Iacobucci et al., ). It is commonly employed as an antihyperalgesia agent intraoperatively and perioperatively (Aveline et al., ; Angst and Clark, ; Abrishamkar et al., ). Given that chronic pain pathophysiology involves glutamate receptor activation, and particularly NMDA receptors (Nijs et al., ; Niesters and Dahan, ; Niesters et al., ; Colloca et al., ), many articles have been published over
European Journal of Pain – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera